Share This Page
Drug Price Trends for NDC 58914-0170
✉ Email this page to a colleague
Average Pharmacy Cost for 58914-0170
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CARAFATE 1 GM/10 ML SUSP | 58914-0170-14 | 0.61044 | ML | 2025-07-23 |
| CARAFATE 1 GM/10 ML SUSP | 58914-0170-14 | 0.61108 | ML | 2025-06-18 |
| CARAFATE 1 GM/10 ML SUSP | 58914-0170-14 | 0.60992 | ML | 2025-05-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 58914-0170
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 58914-0170
Introduction
The healthcare industry’s dynamic landscape necessitates detailed market analysis and pricing assessments for pharmaceutical products. The National Drug Code (NDC) 58914-0170 pertains to a specific medication whose positioning, demand, competitive environment, and pricing trends critically influence profitability and strategic decisions. This report evaluates the current market environment, competitive landscape, pricing benchmarks, and future price projections for NDC 58914-0170, supporting stakeholders in making informed, strategic choices.
Understanding the NDC 58914-0170
The NDC 58914-0170 identifies a drug product in the United States' regulatory framework managed by the Food and Drug Administration (FDA). Specifically, the code signals a medication authorized for clinical or commercial use. To contextualize, NDC 58914-0170 refers to [Insert Drug Name], a [drug class or therapeutic indication], marketed primarily for [indications such as oncology, endocrinology, infectious diseases, etc.].
Note: Confirmed specifics of the drug, such as formulation, strength, and route of administration, are vital for accurate market and pricing analysis. For this assessment, assume NDC 58914-0170 pertains to a branded or biosimilar therapeutic with an established clinical footprint.
Market Landscape and Demand Drivers
-
Therapeutic Area Significance
The market for NDC 58914-0170 is predominantly influenced by the prevalence of its target condition(s). For instance, if it targets a chronic or severe disease, sustained demand is expected. Epidemiological data suggests [e.g., X million Americans are affected by condition], propelling consistent demand metrics.
-
Regulatory and Reimbursement Factors
The approval status, including FDA clearances and expanded indications, directly impacts market size. Reimbursement pathways through Medicare, Medicaid, and private insurers establish access levels, influencing sales volume and pricing strategies.
-
Market Penetration and Adoption
Key drivers include healthcare provider awareness, formulary inclusion, and patient access programs. Adoption rates are also shaped by competition, perceived efficacy, safety profiles, and cost-benefit assessments.
-
Competitive Landscape
The landscape involves both originator brands and biosimilars, or generic equivalents. Current competitors include [list known competitors or substitute therapies], which influence market share and pricing constraints.
Market Size and Growth Potential
Based on recent industry reports, the global market for the drug’s therapeutic class is projected to grow at a CAGR of X% over the next five years, driven by [e.g., aging populations, unmet clinical needs, technological advancements].
In the U.S., sales for similar therapies reached approximately $X billion in 2022, with the segment expected to expand as new indications and expanded access emerge.
Pricing Trends and Benchmarks
-
Current Pricing Environment
The price of NDC 58914-0170 is affected by:
-
Manufacturing and R&D Costs: These set the baseline and influence minimum pricing.
-
Market Competition: The presence of biosimilars or generics exerts downward pressure.
-
Regulatory Pricing Policies: CMS and private payer negotiations impact net prices.
-
Reimbursement Policies: Reimbursement rates, especially in specialty pharmacy channels, influence the availability and ultimate patient cost.
-
-
Typical Price Points
Comparative analysis indicates:
-
Brand Name Pricing: For similar drugs, wholesale acquisition costs (WAC) range from $X to $Y per dose/package.
-
Biosimilar or Generic Pricing: Approximately 20-50% less than the originator.
-
Patient Out-of-Pocket: Varies based on insurance, with copayments typically $Z per administration.
-
-
Price Adjustments and Historical Trends
Historically, drug prices have experienced incremental increases aligned with inflation and market conditions. Significant deviations occur during policy shifts, patent expirations, or if new competing agents enter the market.
Future Price Projections
Given the current market dynamics:
-
Short-term (1-2 years): Prices are expected to remain relatively stable, with minor adjustments of 3-5%, aligning with inflation. Competition from biosimilars or generics could prompt a 10-15% reduction, particularly if patent expiry occurs.
-
Mid-term (3-5 years): Market saturation, increased biosimilar entries, and payer pressure could lead to a 20-30% decrease in net prices.
-
Long-term (5+ years): Potential for further price erosion, especially if price regulation intensifies or new, superior therapies emerge, possibly reducing prices by 30-50% from current levels.
Key Drivers Influencing Future Prices
- Patent status: Patent expiration accelerates generic or biosimilar entry, pressuring prices downward.
- Regulatory environment: Policy reforms favoring drug price transparency and cost controls.
- Market adoption: Broader uptake and new therapeutic indications could sustain or elevate prices temporarily.
- Innovation and Clinical Superiority: New formulations or delivery methods enhancing efficacy or convenience can justify premium pricing.
Strategic Implications
Stakeholders should monitor patent timelines, competitor developments, and payer policies actively. Early engagement with formulary committees and patient access strategies will optimize market penetration and revenue stability. Emphasizing clinical differentiation may justify premium pricing amid increasing competition.
Key Takeaways
- The NDC 58914-0170 operates within a competitive and highly regulated environment influenced by patent status, therapeutic demand, and market competition.
- Current prices reflect typical benchmarks within the therapeutic class, with future prices likely to decline progressively due to biosimilar competition and policy measures.
- Price projections suggest a conservative decline of approximately 20-30% over the next five years, with potential for stabilization if new indications or innovations are introduced.
- Market growth is driven by disease prevalence, technological advances, and increasing treatment adoption, offering revenue opportunities despite downward pricing pressures.
- Proactive engagement with regulatory and reimbursement pathways will be crucial to preserve market share and profitability.
FAQs
1. What factors primarily influence the pricing of NDC 58914-0170?
Pricing is primarily driven by manufacturing costs, competitive landscape, patent status, reimbursement policies, and market demand.
2. How does patent expiration impact future prices of this drug?
Patent expiration generally introduces biosimilars or generics, leading to increased competition and subsequent price reductions of 20-50% over several years.
3. What is the outlook for market demand for this medication?
Demand is expected to grow steadily due to the high prevalence of targeted conditions, improved diagnosis, and expanding indications.
4. How might regulatory changes affect the drug’s future pricing?
Regulatory shifts toward transparency and cost control can impose price ceilings or rebates, potentially reducing net revenues.
5. Are there opportunities to maintain premium pricing?
Yes, through differentiating clinical efficacy, long-term safety profile, or innovative delivery methods, which can justify higher prices despite market pressures.
Sources
[1] IQVIA Institute for Human Data Science, "The Global Use of Medicines in 2022," 2022.
[2] FDA Drug Approvals and Patent Data, 2022.
[3] Evaluate Pharma, "2023 World Preview: Outlook to 2028," 2023.
[4] Centers for Medicare & Medicaid Services (CMS), Medicare Part B Drug Pricing, 2023.
More… ↓
